Fig. 3: Enantiomer-CBD derivative (+)-CBD-oct is does not produce sedative effects at a therapeutic dose.
From: Carvone derived cannabidiol enantiomers as novel anticonvulsants
a Timeline of experiment in C57Bl6 adults, red lines denote administration of (+)-CBD-oct (20 mg*kg-1 p.o.). b, c Representative paths of vehicle (n = 12) and 20 mg*kg-1 ( + )-CBD-oct (n = 7) treated animals in the open field. d Distance traveled over time (Vehicle: 779.112 ± 29.229; ( + )-CBD-oct: 764.036 ± 38.270). e Average speed over time (Vehicle: 2.599 ± 0.0973; ( + )-CBD-oct: 2.544 ± 0.127). f Cumulative distance traveled (Vehicle: 9349.342 ± 1509.491; ( + )-CBD-oct: 9168.429 ± 3739.818). g Total average speed (Vehicle: 2.599 ± 0.421; ( + )-CBD-oct: 2.544 ± 1.039). All values listed are mean ± standard error, p values from Two Way Repeated Measures ANOVA, with Bonferroni post hoc; or t-test. Line graphs are plotted as mean and standard error, and box plots are plotted as median, first and third quartile, and range.
